Erlotinib in the treatment of advanced pancreatic cancer.

Moreover, the hazard ratio showed a trend toward greater benefit of erlotinib in patients who were EGFR FISH negative (HR 0.60, p = 0.08), although the authors concede that the sample size was too small to draw any firm conclusions.

also in 53,322 other papers

Given that even mild-to-moderate rash can confer impairment and distress, its effects on quality of life may be significant ( Gridelli et al 2007 ).

also in 13,097 other papers